Artiva Biotherapeutics Announces Leadership Changes
Ticker: ARTV · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1817241
| Field | Detail |
|---|---|
| Company | Artiva Biotherapeutics, Inc. (ARTV) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-officers
TL;DR
Artiva Biotherapeutics shakes up its board and exec team effective Dec 10, 2025.
AI Summary
Artiva Biotherapeutics, Inc. announced on December 10, 2025, changes in its board of directors and executive officers. The filing details the departure of certain directors and officers, the election of new directors, and updates to compensatory arrangements for key personnel. These changes are effective as of December 10, 2025.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, operational focus, or financial direction, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, potentially affecting the company's stability and performance.
Key Players & Entities
- Artiva Biotherapeutics, Inc. (company) — Registrant
- December 10, 2025 (date) — Effective date of changes
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What specific roles have been affected by these leadership changes?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,' suggesting broad impacts across directorial and executive positions.
When were these leadership changes officially reported?
The Form 8-K was filed on December 12, 2025, reporting events as of December 10, 2025.
What is Artiva Biotherapeutics' primary business?
Artiva Biotherapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), with SIC code 2836.
Where are Artiva Biotherapeutics' principal executive offices located?
The company's principal executive offices are located at 5505 Morehouse Drive, Suite 100, San Diego, California 92121.
What is the Commission File Number for Artiva Biotherapeutics?
The Commission File Number for Artiva Biotherapeutics, Inc. is 001-42179.
Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 12.5 · Accepted 2025-12-12 17:23:56
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share ARTV Nasdaq Glo
Filing Documents
- artv-20251210.htm (8-K) — 56KB
- 0001193125-25-317784.txt ( ) — 173KB
- artv-20251210.xsd (EX-101.SCH) — 31KB
- artv-20251210_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Artiva Biotherapeutics, Inc. By: /s/ Fred Aslan Fred Aslan, M.D. President and Chief Executive Officer Dated: December 12, 2025